DOXYCYCLINE - AN OVERVIEW

There have been no clinically considerable variations while in the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when applied concomitantly with finerenone. A number of doses of forty mg finerenone as soon as-daily had no clinically applicable impact on AUC or Cmax in the BCRP and OATP substrate rosuvasta